Archives of Pediatric Infectious Diseases

Published by: Kowsar

Hepatitis B Seroconversion Rate After Primary Immunization Series with Newly Introduced Pentavalent Vaccine: A Report of Local Study in Alborz Province, Iran, 2016

Reza Arjmand 1 , Mehri Golami 2 , Fariba Shirvani 3 , * , Kumars Pourrostami 1 , Omid Safari 1 , Nasrin Elahimehr 1 , Saeed Nikkhah 1 , Ehsan Zahmatkesh 1 , Mostafa Qorbani 4 and Esfandiar Najafi Tavana 1
Authors Information
1 Department of Pediatric, Emam Ali Hospital, Alborz University of Medical Sciences, Karaj, Iran
2 Alborz University of Medical Sciences, Karaj, Iran
3 Pediatric Infections Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
Article information
  • Archives of Pediatric Infectious Diseases: April 30, 2019, 7 (2); e83565
  • Published Online: April 13, 2019
  • Article Type: Research Article
  • Received: August 24, 2018
  • Revised: March 10, 2019
  • Accepted: March 11, 2019
  • DOI: 10.5812/pedinfect.83565

To Cite: Arjmand R, Golami M, Shirvani F, Pourrostami K , Safari O, et al. Hepatitis B Seroconversion Rate After Primary Immunization Series with Newly Introduced Pentavalent Vaccine: A Report of Local Study in Alborz Province, Iran, 2016, Arch Pediatr Infect Dis. 2019 ; 7(2):e83565. doi: 10.5812/pedinfect.83565.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine. 2008;26(49):6266-73. doi: 10.1016/j.vaccine.2008.09.056. [PubMed: 18848855].
  • 2. World Health Organization. Hepatitis B, Key facts. World Health Organization; 5 july 2017. Available from:
  • 3. MacLachlan JH, Locarnini S, Cowie BC. Estimating the global prevalence of hepatitis B. Lancet. 2015;386(10003):1515-7. doi: 10.1016/S0140-6736(15)61116-3. [PubMed: 26231458].
  • 4. World Health Organization. Hepatitis B fact sheet. World Health Organization; 18 july2018. Available from:
  • 5. Schonberger K, Riedel C, Ruckinger S, Mansmann U, Jilg W, Kries RV. Determinants of Long-term protection after hepatitis B vaccination in infancy: A meta-analysis. Pediatr Infect Dis J. 2013;32(4):307-13. doi: 10.1097/INF.0b013e31827bd1b0. [PubMed: 23249904].
  • 6. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: A meta-analysis. Vaccine. 2010;28(3):623-31. doi: 10.1016/j.vaccine.2009.10.068. [PubMed: 19887132].
  • 7. Kabir A, Alavian SM, Ahanchi N, Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res. 2006;36(4):265-71. doi: 10.1016/j.hepres.2006.08.001. [PubMed: 16965939].
  • 8. Lankarani KB, Taghavi AR, Agah S, Karimi A. Comparison of intradermal and intramuscular administration of hepatitis B vaccine in neonates. Indian J Gastroenterol. 2001;20(3):94-6. [PubMed: 11400817].
  • 9. Hassan S, Ziba F. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine. 2007;25(17):3511-4. doi: 10.1016/j.vaccine.2005.09.037. [PubMed: 17400337].
  • 10. Hadi N, Hadi N. Assessment of anti-HBs antigen in 6- to 9-year-old children routinely vaccinated via vaccination program in Iran. Med Princ Pract. 2007;16(4):306-9. doi: 10.1159/000102154. [PubMed: 17541297].
  • 11. Adibi P, Ghassemian R, Alavian SM, Ranjbar M, Mohammadalizadeh AH, Nematizadeh F, et al. Effectiveness of hepatitis B vaccination in children of chronic hepatitis B mothers. Saudi Med J. 2004;25(10):1414-8. [PubMed: 15494813].
  • 12. Saffar MJ, Rezai MS. Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. Indian Pediatr. 2004;41(12):1232-7. [PubMed: 15623904].
  • 13. Tazhibi M, Hajivandi A, Tafti AD, Fallahzadeh H. The efficacy of hepatitis B vaccine in Iranian population: A systematic review and meta-analysis. J Educ Health Promot. 2014;3:53. doi: 10.4103/2277-9531.134741. [PubMed: 25077146]. [PubMed Central: PMC4114169].
  • 14. Saffar H, Ajami A, Saffar MJ, Shojaei J, Sotudeh-Anvari M, Shams-Esfandabad K, et al. Prevalence of hepatitis B virus seromarkers in young adults vaccinated at birth; impact on the epidemiology of hepatitis B infection in iran. Hepat Mon. 2014;14(5). e17263. doi: 10.5812/hepatmon.17263. [PubMed: 24829589]. [PubMed Central: PMC4013494].
  • 15. Dahifar H. Immunogenecity of cuban hepatitis B vaccine in Iranian children. Arch Iranian Med. 2004;7(2):89-92.
  • 16. Rostami N, Ghaffari V, Samaie H. Comparison of immune response to hepatitis B vaccine between term and preterm infants at birth. Arch Clin Infect Dis. 2006;7(1):11-4.
  • 17. Moradi A, Khodabakhshi B, Ghaemi E, Mansourian AR, Sarikhani A, Saeidi M. [The response rate to hepatitis B vaccine in under one-year children in Gorgan, Iran]. J GorganUni Med Sci. 2008;10(2):50-3. Persian.
  • 18. Huu TN, Phuong NT, Toan NT, Thang HV. Immunogenicity and safety of quinvaxem(R) (diphtheria, tetanus, whole-cell pertussis, hepatitis B and haemophilus influenzae type B vaccine) given to vietnamese infants at 2 to 4 months of age. Southeast Asian J Trop Med Public Health. 2015;46(4):753-63. [PubMed: 26867396].
  • 19. Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review. Vaccine. 2013;31(21):2506-16. doi: 10.1016/j.vaccine.2012.12.012. [PubMed: 23257713].
  • 20. Eregowda A, Lalwani S, Chatterjee S, Vakil H, Ahmed K, Costantini M, et al. A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants. Hum Vaccin Immunother. 2013;9(9):1903-9. doi: 10.4161/hv.25166. [PubMed: 23783081]. [PubMed Central: PMC3906354].
  • 21. Rezaee R, Aghcheli B, Poortahmasebi V, Qorbani M, Alavian SM, Jazayeri SM. Prevalence of national responsiveness to HBV vaccine after 22 years of Iranian Expanded Program on Immunization (EPI): A systematic review and meta-analysis study. Hepat Mon. 2015;15(5). e23618. doi: 10.5812/hepatmon.15(04)2015.23618. [PubMed: 26045701]. [PubMed Central: PMC4451270].
  • 22. Najafi F, Sayehmiri K, Najafi R. Efficacy of hepatitis B vaccination in under five-year-old children in Iran: A systematic review and meta-analysis study. Hepat Mon. 2018;18(6). e65385. doi: 10.5812/hepatmon.65385.
  • 23. Von Kriesa R, Kaliesa H, Schmittb HJ. DTPa (+)/Hib combination vaccines: The German experience. Anals De Pediatria. 2003;58(S5.21).
  • 24. Verma C, Faridi MM, Narang M, Kaur IR. Anti-HBs titers following pentavalent immunization (DTwP-HBV-Hib) in term normal weight vs low birthweight infants. Indian Pediatr. 2018;55(5):395-9. [PubMed: 29428913].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments